ArticleClinical and experimental pediatrics2026
Thrombocytopenia in preterm infants born to mothers with systemic lupus erythematosus: a retrospective cohort study.
Article in Clinical and experimental pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Leukocyte Profiles in Preterm Infants Born to Mothers with Systemic Lupus Erythematosus: An Exploratory Matched Cohort Study.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThrombocytopenia in preterm infants born to mothers with systemic lupus erythematosus (SLE) is poorly characterized, despite its potential link to adverse outcomes. Our understanding of platelet dynamics, risk factors, and clinical outcomes in this population is limited, necessitating further investigation. PURPOSE: This study aimed to characterize the incidence, timing, and severity of thrombocytopenia in this population; to identify associated maternal and neonatal risk factors; and to evaluate its association with adverse outcomes.
methodsWe included 154 preterm infants born to mothers with SLE who were admitted to Shanghai Children's Medical Center within 24 hours of birth between 2014 and 2024. Logistic regression was used to identify risk factors and outcomes associated with neonatal thrombocytopenia.
resultsThrombocytopenia (platelet count < 150 ×109/L) occurred in 32.5% of infants, and severe form (< 50 ×109/L) occurred in 4.6%. The condition peaked on postnatal days 4-5, and 16% of affected infants required intervention. Late preterm infants (adjusted odds ratio [aOR], 0.15; 95% confidence interval [CI], 0.05-0.42), moderate preterm infants (aOR, 0.26; 95% CI, 0.09-0.76), and maternal hydroxychloroquine use (aOR, 0.19; 95% CI, 0.07-0.52) were protective factors. In contrast, maternal hypertensive disorders of pregnancy (HDP; aOR, 3.41; 95% CI, 1.06-10.93) increased the risk. Infants with thrombocytopenia had significantly higher risks of intracranial hemorrhage (aOR, 4.27; 95% CI, 1.65-11.00) and late-onset sepsis (aOR, 11.00; 95% CI, 1.23-98.14).
conclusionPreterm infants exposed to maternal SLE frequently developed thrombocytopenia, but most cases were self-limited. Key risk modulators included gestational age, maternal HDP, and hydroxychloroquine use. Furthermore, thrombocytopenia was significantly associated with neonatal morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.